Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16055552 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL2670982 | 0.83 | CA2 (0.39) | ALDH1A1 | |
| SCHEMBL2670983 | 0.83 | CA2 (0.39) | ALDH1A1 | |
| SCHEMBL3402317 | 0.82 | APP (0.39) | MRGPRX4KDM4CKDM5AKDM5BPGR | |
| SCHEMBL29327244 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL2831306 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL18297876 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL19354024 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL2831486 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TP53TSHRHIF1ACYP3A4 | |
| SCHEMBL2829952 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TP53TSHRHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970236-B1 | PYRIDIN-4-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-30 | — | — | EP | disclosed |
| US-9617250-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-04-11 | — | — | US | disclosed |
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2970236-A1 | PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-102471328-B | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD | 2015-04-01 | — | — | CN | disclosed |
| WO-2014141171-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8658675-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-25 | — | — | US | disclosed |
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2454255-B1 | PYRIDIN-4-YL DERIVATIVES AS S1P1/EDG1 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009109906-A1 | PYRIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109904-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | CD4, IL2, CD47 | ALDH1A1 448/4885TP53 1953/4885TSHR 1018/4885 |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | ALDH1A1 1141/4885TP53 4175/4885TSHR 580/4885 |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | ALDH1A1 680/4885TP53 387/4885TSHR 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.